Solti Breast Cancer Research Group
Clinical trials sponsored by Solti Breast Cancer Research Group, explained in plain language.
-
New combo targets Hard-to-Treat breast cancer in early trial
Disease control CompletedThis early-phase study tested a new drug combination for people with advanced HER2-positive breast cancer that has a specific gene change (PIK3CA mutation). The goal was to find a safe dose of the study drug ipatasertib when given with two standard drugs (pertuzumab and trastuzum…
Phase: PHASE1 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
Virus and immune drug combo shows promise against stubborn breast cancer
Disease control CompletedThis study tested a combination of two drugs—talimogene laherparepvec (T-VEC), a virus that attacks cancer cells, and atezolizumab, an immunotherapy—in 28 women with early-stage breast cancer that still had tumor left after standard chemotherapy. The goal was to see if this combo…
Phase: EARLY_PHASE1 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New test may predict olaparib success in advanced breast cancer
Knowledge-focused CompletedThis study looked at 65 people with advanced HER2-negative breast cancer who have certain gene mutations. Researchers used a test called RAD51-foci to see if it could predict how well the drug olaparib would work. The goal was to find a better way to match patients with the right…
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Knowledge-focused
Last updated May 20, 2026 11:55 UTC